ReviewFrontiers in immunology2026
Hidradenitis suppurativa and psoriasis: shared immunological links with metabolic-associated steatotic liver disease.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inflammatory skin conditions such as hidradenitis suppurativa and psoriasis vulgaris exhibit a significantly elevated prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD), with studies indicating rates as high as 57% among affected individuals. This narrative review explores the underlying immunological mechanisms that connect HS and psoriasis with MASLD, emphasising the role of chronic systemic inflammation, immune dysregulation, and shared immunologic links between the diseases. This article also urges for enhanced awareness among dermatologists regarding the potential pharmacological interventions for patients with concurrent HS or psoriasis and MASLD, including glucagon-like peptide-1 receptor agonists and biologics, while acknowledging the need for further research to elucidate the efficacy and safety of these treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.